Revelation Biosciences Earnings Estimate

REVB Stock  USD 3.05  0.01  0.33%   
The next projected EPS of Revelation Biosciences is estimated to be -1.485 with future projections ranging from a low of -2.05 to a high of -0.92. Revelation Biosciences' most recent 12-month trailing earnings per share (EPS TTM) is at -246.21. Please be aware that the consensus of earnings estimates for Revelation Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Revelation Biosciences is projected to generate -1.485 in earnings per share on the 30th of June 2025. Revelation Biosciences earnings estimates show analyst consensus about projected Revelation Biosciences EPS (Earning Per Share). It derives the highest and the lowest estimates based on Revelation Biosciences' historical volatility. Many public companies, such as Revelation Biosciences, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Revelation Biosciences' earnings estimates, investors can diagnose different trends across Revelation Biosciences' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about (26.5 K)Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

Revelation Biosciences Earnings Estimation Breakdown

The calculation of Revelation Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Revelation Biosciences is estimated to be -1.485 with the future projection ranging from a low of -2.05 to a high of -0.92. Please be aware that this consensus of annual earnings estimates for Revelation Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-2.11
-2.05
Lowest
Expected EPS
-1.485
-0.92
Highest

Revelation Biosciences Earnings Projection Consensus

Suppose the current estimates of Revelation Biosciences' value are higher than the current market price of the Revelation Biosciences stock. In this case, investors may conclude that Revelation Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Revelation Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2025Current EPS (TTM)
150.0%
-2.11
-1.485
-246.21

Revelation Biosciences Earnings per Share Projection vs Actual

Actual Earning per Share of Revelation Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Revelation Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Revelation Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Revelation Biosciences Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Revelation Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Revelation Biosciences should always be considered in relation to other companies to make a more educated investment decision.

Revelation Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Revelation Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-05-08
2025-03-31-6.88-2.114.7769 
2025-03-20
2024-12-31-10.32-4.985.3451 
2024-11-07
2024-09-30-2.84-0.842.070 
2024-08-09
2024-06-30-1.8-5.13-3.33185 
2024-05-10
2024-03-31-5.38-2.462.9254 
2024-03-22
2023-12-31-13.77-8.335.4439 
2023-11-09
2023-09-30-0.3-0.42-0.1240 
2023-08-11
2023-06-30-0.4-0.250.1537 
2023-05-22
2023-03-31-0.652.793.44529 
2023-03-30
2022-12-31-1.75-1.690.06
2022-11-10
2022-09-30-3.15-2.11.0533 
2022-08-15
2022-06-30-4.9-4.20.714 
2022-04-15
2022-03-31-4.9-16.45-11.55235 
null
nullnullnullnull
2019-10-24
2019-09-300.680.690.01
2019-07-24
2019-06-300.640.650.01
2019-04-29
2019-03-310.610.620.01
2019-01-29
2018-12-310.610.59-0.02
2018-11-09
2018-09-300.650.650.0

About Revelation Biosciences Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Revelation Biosciences earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Revelation Biosciences estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Revelation Biosciences fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-40.5 B-38.5 B
Earnings Yield(3.96)(3.76)
Price Earnings Ratio(0.25)(0.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(246.21)
Return On Assets
(0.55)
Return On Equity
(2.33)
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.